Conjugates of Cisplatin and Cyclooxygenase Inhibitors as Potent Antitumor Agents Overcoming Cisplatin Resistance
暂无分享,去创建一个
[1] S. Lippard,et al. Synthesis and characterization of Pt(IV) fluorescein conjugates to investigate Pt(IV) intracellular transformations. , 2013, Bioconjugate chemistry.
[2] E. Wexselblatt,et al. What do we know about the reduction of Pt(IV) pro-drugs? , 2012, Journal of inorganic biochemistry.
[3] M. Jakupec,et al. Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs. , 2012, Dalton transactions.
[4] M. I. Setyawati,et al. Tuning the activity of platinum(IV) anticancer complexes through asymmetric acylation. , 2012, Journal of medicinal chemistry.
[5] S. Lippard,et al. Redox activation of metal-based prodrugs as a strategy for drug delivery. , 2012, Advanced drug delivery reviews.
[6] Michael M Gottesman,et al. Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes , 2012, Pharmacological Reviews.
[7] L. Galluzzi,et al. Molecular mechanisms of cisplatin resistance , 2012, Oncogene.
[8] Justin J. Wilson,et al. Synthesis, characterization, and cytotoxicity of platinum(IV) carbamate complexes. , 2011, Inorganic chemistry.
[9] Jian-Hua Fu,et al. Celecoxib Antagonizes the Cytotoxicity of Cisplatin in Human Esophageal Squamous Cell Carcinoma Cells by Reducing Intracellular Cisplatin Accumulation , 2011, Molecular Pharmacology.
[10] R. Gust,et al. Synthesis and biological activities of transition metal complexes based on acetylsalicylic acid as neo-anticancer agents. , 2010, Journal of medicinal chemistry.
[11] Shonagh Walker,et al. The status of platinum anticancer drugs in the clinic and in clinical trials. , 2010, Dalton transactions.
[12] Lawrence J Marnett,et al. Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. , 2010, Cancer research.
[13] S. Mandal,et al. COX-2 as a target for cancer chemotherapy , 2010, Pharmacological reports : PR.
[14] L. Marnett,et al. Differential Sensitivity and Mechanism of Inhibition of COX-2 Oxygenation of Arachidonic Acid and 2-Arachidonoylglycerol by Ibuprofen and Mefenamic Acid† , 2009, Biochemistry.
[15] L. Marnett. The COXIB experience: a look in the rearview mirror. , 2009, Annual review of pharmacology and toxicology.
[16] Heather R. Roberts,et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. , 2009, Carcinogenesis.
[17] M. Jakupec,et al. Novel bis(carboxylato)dichlorido(ethane-1,2-diamine)platinum(IV) complexes with exceptionally high cytotoxicity. , 2008, Journal of inorganic biochemistry.
[18] G. Peters,et al. Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. , 2008, Biochemical pharmacology.
[19] M. Jakupec,et al. Novel di- and tetracarboxylatoplatinum(IV) complexes. Synthesis, characterization, cytotoxic activity, and DNA platination. , 2007, Journal of medicinal chemistry.
[20] Zhiqiang Shen,et al. Copper-aspirin complex inhibits cyclooxygenase-2 more selectively than aspirin. , 2007, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
[21] D. Stewart,et al. Mechanisms of resistance to cisplatin and carboplatin. , 2007, Critical reviews in oncology/hematology.
[22] Yiwei Li,et al. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. , 2007, Mini reviews in medicinal chemistry.
[23] M. Dolan,et al. Molecular mechanisms of resistance and toxicity associated with platinating agents. , 2007, Cancer treatment reviews.
[24] G. Kucera,et al. Cyclooxygenase inhibition and hyperthermia for the potentiation of the cytotoxic response in ovarian cancer cells. , 2007, Gynecologic oncology.
[25] B. Erovic,et al. Inhibition of cytotoxicity of cisplatin by cyclooxygenase-2 inhibitor nimesulide in head and neck cancer cell lines. , 2005, Oncology reports.
[26] L. Juillerat-Jeanneret,et al. Synthesis and characterization of platinum(IV) anticancer drugs with functionalized aromatic carboxylate ligands: influence of the ligands on drug efficacies and uptake. , 2005, Journal of medicinal chemistry.
[27] I. Cree,et al. Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors , 2005, Anti-cancer drugs.
[28] S. Byun,et al. Augmentation of cisplatin sensitivity in cisplatin‐resistant human bladder cancer cells by modulating glutathione concentrations and glutathione‐related enzyme activities , 2005, BJU international.
[29] J. Hayakawa,et al. Mechanisms of platinum drug resistance. , 2005, Trends in pharmacological sciences.
[30] C. S. Allardyce,et al. Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. , 2005, Journal of the American Chemical Society.
[31] R. Botting,et al. Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition , 2004, Pharmacological Reviews.
[32] E. Martinelli,et al. Prognostic Role of the Ratio between Cyclooxygenase-2 in Tumor and Stroma Compartments in Cervical Cancer , 2004, Clinical Cancer Research.
[33] D. Elder,et al. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] M. Hall,et al. Platinum(IV) antitumour compounds: their bioinorganic chemistry , 2002 .
[35] N. Maggiano,et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] N. Maggiano,et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] S. Grösch,et al. COX‐2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX‐2 inhibitor celecoxib , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[38] K. Hattori,et al. Synergistic effect of indomethacin with adriamycin and cisplatin on tumor growth. , 2001, Biological & pharmaceutical bulletin.
[39] J. Essigmann,et al. Mechanisms of resistance to cisplatin. , 2001, Mutation research.
[40] S. Minoura,et al. Indomethacin increases the cytotoxicity of cis-platinum and 5-fluorouracil in the human uterine cervical cancer cell lines SKG-2 and HKUS by increasing the intracellular uptake of the agents , 2001, International Journal of Clinical Oncology.
[41] L. Marnett,et al. Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. , 2000, Journal of medicinal chemistry.
[42] J. Reedijk,et al. Can Pt(IV)—amine complexes act as ‘prodrugs’? , 1998 .
[43] Sunhee Choi,et al. Reduction and Anticancer Activity of Platinum(IV) Complexes , 1998 .
[44] L. Kèlland,et al. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. , 1996, Anticancer research.
[45] M. Galanski,et al. Carboxylation of Dihydroxoplatinum(IV) Complexes via a New Synthetic Pathway. , 1996, Inorganic chemistry.
[46] R. Perez,et al. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. , 1994, Cancer research.
[47] L. Kèlland,et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. , 1993, Cancer research.
[48] L. Kèlland,et al. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines. , 1992, Cancer research.
[49] E. Pettersen,et al. The binding of cis-dichlorodiammineplatinum(II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro. , 1992, British Journal of Cancer.
[50] H. Earl,et al. A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] R. Lange,et al. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). , 1973, Cancer research.
[52] M. Jakupec,et al. Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. , 2011, Journal of inorganic biochemistry.
[53] C. Tsatsanis,et al. Signalling networks regulating cyclooxygenase-2. , 2006, The international journal of biochemistry & cell biology.
[54] B. Sikic,et al. Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion , 2004, Cancer Chemotherapy and Pharmacology.
[55] T. Kuczek,et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer , 2000, Cancer Chemotherapy and Pharmacology.
[56] K. Lemma,et al. Kinetics and mechanism for reduction of oral anticancer platinum(IV) dicarboxylate compounds by L-ascorbate ions , 2000 .
[57] T. Hambley,et al. The Influence of the Axial Ligands of a Series of Platinum(IV) Anti-Cancer Complexes on Their Reduction to Platinum(II) and Reaction With DNA , 1995 .
[58] W. Mason. Platinum(ii)-catalyzed substitutions of platinum(iv) complexes , 1972 .